Support of Strawman Solution and Limited Preventative Registration proposals
To Whom It May Concern, Please note that Eli Lilly and Company supports adoption of both the "Strawman Solution" and the "Limited Preventative Registration" proposals in order to enhance our ability to protect our trademarks when used as or in domain names in new gTLDs. In particular we support the Limited Preventative Registration proposal as a cost-efficient and streamlined method to register names across hundreds of new registries as opposed to the current mechanism. Our company is the applicant for the .LILLY gTLD (Application number 1-1018-57217). Since 2004, we (or one of our affiliates) have filed 97 UDRP proceedings covering 446 domains with respect to our trademarks. We have also sent cease and desist letters which have resulted in the successful transfer of 25 domains. In total, we have successfully obtained 471 domains containing our trademarks registered and used in bad faith by third parties. Our vigilance has been fueled by our concern about the misleading and potentially harmful use of our trademarks in the domain names of websites, especially in light of the proliferation of illegal online drug sellers and the obvious risk to consumer and patient safety. While we understand that these proposals may not eliminate the bad faith use and registration of domains incorporating our marks, we believe these proposals will provide cost effective assistance to Lilly and other trademark owners to help manage what we anticipate will be an explosion of cybersquatting with the introduction of the new gLTDs. Thank you for your consideration. Please let me know if you have any questions. Bruce Longbottom Assistant General Counsel Trademarks, Copyrights and Information Technology Eli Lilly and Company phone: (317) 651-1346 fax: (317) 276-1919 email: longbottom_bruce@xxxxxxxxx CONFIDENTIALITY NOTICE: This email message (including all attachments) is for the sole use of the intended recipient(s) and may contain confidential and privileged information. Any unauthorized review, use, disclosure, copying or distribution is strictly prohibited. If you are not the intended recipient, please contact the sender by reply email and destroy all copies of the original message.